No Data
No Data
No Data
No Data
No Data
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California.
GlobeNewswireApr 10 20:00
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience With QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. ("Qualigen" or the "Company," Nasdaq: QLGN) today announces that a poster featuring its early clinical experience wit
GlobeNewswireApr 9 20:00
Qualigen Therapeutics Ends Deal With Pan-RAS Holdings
TipRanksMar 29 04:25
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersJanux Therapeutics (NASDAQ:JANX) stock increased by 189.9% to $43.78 during Tuesday's regular session. The company's market cap stands at $2.0 billion. Viking Therapeutics (NASDAQ:VKTX) shares
BenzingaFeb 28 01:31
Qualigen Therapeutics Secures Investment and Expands Financing Options
TipRanksFeb 27 20:12
Qualigen Therapeutics Inks Exclusive RAS Program Deal
TipRanksFeb 23 05:25
No Data
No Data